Defining cancer cachexia in head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6561-6567

  Richey, Luke M ^a   George, Jonathan R ^a   Couch, Marion E ^a   Kanapkey, Brian K ^a   Yin, Xiaoying ^a   Cannon, Trinitia ^a   Stewart, Paul W ^b   Weissler, Mark C ^a   Shores, Carol G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; HEMOGLOBIN; INTERLEUKIN 6; RNA;

ADULT; ARTICLE; BLOOD LEVEL; CACHEXIA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUALITY OF LIFE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

AGED; CACHEXIA; CARCINOMA, SQUAMOUS CELL; CYTOKINES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; QUALITY OF LIFE; RNA, MESSENGER;

EID: 36749087038     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0116     Document Type: Article

References (24)

1. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and neck cancer patients. Part 1. Diagnosis, impact on quality of life, survival, and treatment. Head and Neck 2007;29:401-11.
2. Ramosa EJ, Suzuki S, Marks D, Inui A, Asakawa A, Mequid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004;7:427-34.
3. Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78:554-61.
4. Martignoni M, Kunze P, Hildebrandt W, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005;11:5802-8.
5. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6.
6. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003;97:1211-6.
7. George J, Cannon T, Lai V, et al. Cancer cachexia syndrome in head and neck cancer patients. Part 2. Pathophysiology. Head and Neck 2007;29:497-507.
8. Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer 1999;80:444-7.
9. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
10. Hussey HJ, T odorov PT, Field WN, et al. Effect of a fluorinated pyrimidine on cachexia and tumor growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 2000;83:56-62.
11. Sanders PM, Tisdale MJ. Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. Br J Cancer 2004;90:1274-8.
12. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998;58:2353-8.
13. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001;84:1599-601.
14. Wang Z, Corey E, Hass GM, et al. Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 2003;105:123-9.
15. Deans DA, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KC, Ross JA. Expression of the proteolysis-inducing factor core peptide mRNA is up-regulated in both tumour and adjacent normal tissue in gastrooesophageal malignancy. Br J Cancer 2006;94:731-6.
16. Bruera E. ABC of palliative care: anorexia, cachexia, and nutrition. Br Med J1997;315:1219-22.
17. Fearon KCH, Moses AGW. Cancer cachexia. Int J Cardiol 2002;85:73-81.
18. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006;12:3746-50.
19. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
20. Rubin H. Cancer cachexia: its correlations and causes. Proc Natl Acad Sci US A 2003;100:5384-9.
21. Klein B, Wijdenes J, Zhang X-G, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-204.
22. Van Zaanen HC, Lokhorst HM, Aarden LA. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 1998;102:783-90.
23. Zaki MH, Nemeth JA, Trikha M. CNTO 328, amonoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004;11:592-5.
24. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol Head Neck Surg 1999;120:427-36.